Key terms
About XBIO
Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest XBIO news
Mar 23
2:00am ET
Xenetic Biosciences, Inc. Under Pressure: Shareholder Activism Threatens Stability and Financial Future
Mar 22
8:31am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Xenetic Biosciences (XBIO) and Dianthus Therapeutics (DNTH)
Feb 12
9:35am ET
Xenetic Biosciences Shares Insights on Oncology Platform
Jan 17
9:10am ET
Xenetic enters research agreement with University of Virginia
No recent news articles are available for XBIO
XBIO Financials
Key terms
Ad Feedback
XBIO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
XBIO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range